# OnCo record rejuv-agenda-latency-outruns-the-evidence (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/rejuv-agenda-latency-outruns-the-evidence/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "rejuv-agenda-latency-outruns-the-evidence" ;
  schema:name "The newest treatments have not existed long enough for their late effects to appear"@en ;
  schema:description "A second cancer after radiotherapy can take forty years to appear. Immunotherapy and antibody-drug conjugates have been in first-line use for a few. Being told a new drug has no late effects usually means nobody has been followed long enough to see one."@en ;
  schema:url <https://onco.cc/bottlenecks/rejuv-agenda-latency-outruns-the-evidence/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1505949> ;
  onco:tag "rejuvenation", "survivorship", "open-problem", "second-cancers", "latency" ;
  onco:related <https://onco.cc/terms/rejuv-second-radiotherapy-dose-field-and-age/>, <https://onco.cc/terms/rejuv-second-platinum-and-parp-inhibitors/>, <https://onco.cc/technologies/rejuv-tx-secondary-t-cell-malignancy/>, <https://onco.cc/technologies/rejuv-tx-gene-modified-follow-up/>, <https://onco.cc/technologies/rejuv-tx-second-cancers/>, <https://onco.cc/technologies/rejuv-paed-second-cancers/>, <https://onco.cc/ideas/idea-rejuv-second-cancer-latency-cohort-for-new-drugs/>, <https://onco.cc/bottlenecks/rejuv-agenda-late-effects-are-not-counted/>, <https://onco.cc/roadmaps/rejuvenation-roadmap/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> .